Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of a cb1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease

a technology of cb1 receptor and product, which is applied in the field of combination of a cb1 receptor antagonist and a product which activates dopaminergic neurotransmission in the brain, can solve the problems of significant side effects, wear-off effect, and decrease in effectiveness, and achieve the effect of reducing side effects and potentiating symptoms

Inactive Publication Date: 2007-08-23
AVENTIS PHARMA SA (US)
View PDF2 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent text describes the use of a combination of CB1 receptor antagonists and products that activate dopaminergic neurotransmission in the brain to treat Parkinson's disease. This combination can enhance the effects of dopaminergic monotherapy and reduce side effects, such as dyskinesias."

Problems solved by technology

However, after several years, fluctuations in response (on-off effect), a decrease in its effectiveness as the disease progresses (wearing-off effect) and in particular dyskinesias (involuntary abnormal movements) are observed in the majority of patients.
Significant side effects have also been observed with these therapies.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of a cb1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
  • Combination of a cb1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
  • Combination of a cb1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0406] N-{1-[Bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide can be prepared by carrying out the preparation in the following way: 0.042 cm3 of phosphorus trichloride is added to a solution of 0.144 g of N-{1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-N-(1-oxidopyrid-3-yl)methylsulfonamide in 5 cm3 of chloroform and then the mixture is heated to the reflux temperature. After stirring for 1 hour 30 minutes, the reaction mixture is allowed to return to normal temperature, 5 cm3 of 0.1N hydrochloric acid are then added to the mixture, and then the mixture is stirred and separated by settling. The organic phase is diluted with 20 cm3 of chloroform, dried over magnesium sulfate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa). The residue is chromatographed on a column of silica gel (particle size 0.063-0.200 mm, height 9 cm, diameter 1.8 cm), elution being carried out under a pressure of 0.1 bar of argon with a mixture of dichlorometha...

example 2

Method 1:

[0407] N-{1-[Bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide can be prepared by carrying out the preparation in the following way: 1.0 g of cesium carbonate is added to a mixture of 1.23 g of 1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}methylsulfonate and of 0.66 g of N-(3,5-difluorophenyl)methylsulfonamide in 25 cm3 of dioxane. After stirring for 5 hours at the reflux temperature and then for 20 hours at 20° C., 50 cm3 of diethyl ether and 30 cm3 of brine are added to the reaction mixture and then the reaction mixture is stirred and separated by settling. The organic phase is dried over magnesium sulfate, filtered and then concentrated to dryness at 50° C. under reduced pressure (2.7 kPa). The orange oil obtained is chromatographed on a column of silica gel (particle size 0.040-0.063 mm, height 25 cm, diameter 2.0 cm), elution being carried out under a pressure of 0.5 bar of argon with a mixture of cyclohexane and of ethyl acetate (65 / 35 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their use in the treatment of Parkinson's disease.

Description

[0001] This application is a continuation of U.S. application Ser. No. 10 / 786,810, filed Feb. 25, 2004, now allowed, which is a continuation of International application No. PCT / FR02 / 02,946, filed Aug. 28, 2002, both of which are incorporated herein by reference in their entirety; which claims the benefit of priority of French Patent Application No. 01 / 11,200, filed Aug. 29, 2001.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates to the combination of one or more CB1 receptor antagonists and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their use in the treatment of Parkinson's disease. [0004] 2. Description of the Art [0005] CB1 receptor antagonists have been developed for the treatment of schizophrenia (D. Kendall, Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs, 2(1), 112-122, 2000), for their effect on food intake (G. Colombo et al....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/18A61K45/00A61K31/198A61K31/397A61K31/4353A61K31/4427A61K45/06A61P25/00A61P25/16A61P43/00
CPCA61K9/4858A61K31/397A61K31/4353A61K45/06A61K2300/00A61P25/00A61P25/16A61P43/00
Inventor BENAVIDES, JESUSBOCCIO, DANIELHENIN, YVETTEPIOT-GROSJEAN, ODILE
Owner AVENTIS PHARMA SA (US)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com